Invention Grant
- Patent Title: Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins
-
Application No.: US15145135Application Date: 2016-05-03
-
Publication No.: US09758582B2Publication Date: 2017-09-12
- Inventor: Nagaraj Govindappa , Kedarnath Sastry , Maria Melina Soares
- Applicant: BIOCON LIMITED
- Applicant Address: IN
- Assignee: BIOCON LIMITED
- Current Assignee: BIOCON LIMITED
- Current Assignee Address: IN
- Agency: Moore & Van Allen, PLLC
- Agent Marianne Fuierer
- Priority: IN1689/CHE/2012 20120430; IN1690/CHE/2012 20120430
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K38/10 ; A61K38/18 ; A61K39/395 ; C07K14/495 ; C07K14/00 ; C07K14/65 ; C07K14/705 ; C07K16/32 ; G01N33/68 ; A61K38/17 ; A61K45/06 ; C07K7/08 ; C07K14/71 ; C07K16/30 ; A61K39/00 ; A61K38/00
Abstract:
The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
Public/Granted literature
- US20160237155A1 TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME Public/Granted day:2016-08-18
Information query
